Recent Updates
Recently added Catalysts
PROF Positive Sentiment

Profound Medical and Akumin Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO®

Monday, February 19, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Profound Medical Corp. has entered into a multi-center commercial agreement with Akumin Inc. for its TULSA-PRO® technology. This partnership aims to enhance the availability of incision-free therapies for tissue ablation across multiple imaging centers in the U.S. The collaboration is expected to strengthen Profound's market presence.
Price reaction · baseline $8.5 (2024-02-16 close) · 15 other PROF headline(s) in the window, move may be shared
day 0 close · peak
-2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Profound Medical expands its market reach through a new agreement.
  • Collaboration with Akumin enhances service offerings in the U.S.
  • TULSA-PRO® is positioned as a customizable, incision-free therapy.

Full Press Release Details

TORONTO, May 06, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the signing of a multi-site imaging center agreement for TULSA-PRO® with Akumin Inc. (NASDAQ/TSX:AKU) (“Akumin”), a leading provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States.

Frequently Asked Questions

What is the TULSA-PRO® technology?

TULSA-PRO® is a customizable, incision-free therapy developed by Profound Medical for tissue ablation.

Who is Akumin?

Akumin Inc. is a leading provider of outpatient diagnostic imaging services in the U.S.

What does the agreement entail?

The agreement involves a multi-center collaboration to enhance the availability of TULSA-PRO®.

When was the agreement announced?

The agreement was announced on May 06, 2021.

ShareAdd on Google
Tags: PROF Viatris Investor Conferences Healthcare Profound Medical Akumin TULSA-PRO medical device tissue ablation
Last updated: Feb 19, 2024

Biotech snapshot

Cash runway
$38M liquidity · $4M/mo burn
~10 mo
Medium dilution risk